Second transplants for multiple myeloma relapsing after a previous autotransplant-reduced-intensity allogeneic vs autologous transplantation

Bone Marrow Transplantation

Volumn 49, Issue 3, 2014, Pages 416-421

  Freytes, C O ^a   Vesole, D H ^b   Lerademacher, J ^c   Zhong, X ^c   Gale, R P ^d   Kyle, R A ^e   Reece, D E ^f   Gibson, J ^g   Schouten, H C ^h   McCarthy, P L ⁱ   Lonial, S ^j   Krishnan, A Y ^k   Dispenzieri, A ^e   Hari, P N ^c  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

^e MAYO CLINIC ROCHESTER   (United States)

^f UNIVERSITY OF TORONTO   (Canada)

^g ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^h MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁱ ROSWELL PARK CANCER INSTITUTE   (United States)

^j EMORY UNIVERSITY HOSPITAL   (United States)

^k CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

more..

Author keywords

allogeneic; multiple myeloma; salvage transplant

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUDARABINE; IMMUNOSUPPRESSIVE AGENT; MELPHALAN; METHOTREXATE; TACROLIMUS;

ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER GROWTH; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HIGH RISK PATIENT; HUMAN; KARNOFSKY PERFORMANCE STATUS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NONMYELOABLATIVE CONDITIONING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REDUCED INTENSITY CONDITIONING; RETRANSPLANTATION; SURVIVAL TIME; YOUNG ADULT; ALLOTRANSPLANTATION; AUTOTRANSPLANTATION; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE COURSE; IMMUNOSUPPRESSIVE TREATMENT; LONGITUDINAL STUDY; MORTALITY; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PROCEDURES; PROPORTIONAL HAZARDS MODEL; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADULT; AGED; DISEASE PROGRESSION; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MULTIPLE MYELOMA; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; PROPORTIONAL HAZARDS MODELS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 84904240000     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2013.187     Document Type: Article

References (30)

1. Rajkumar SV. Treatment of multiple myeloma. Nat Rev Clin Oncol 2011; 8: 479-491.
2. Jacubowiak J. Management strategies for relapsed/refractory multiple myeloma: current clinical perspectives. Semin Hematol 2012; 49(Suppl 1): S16-S32.
3. Kumar SK, Lee JH, LaHuerta JJ, Morgan G, Richardson PG, Crowley J et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia 2012; 26: 149-157.
4. Bensinger W, Rotta M, Storer B, Chauncey T, Holmberg L, Becker P et al. Allo-SCT for multiple myeloma: a review of outcomes at a single transplant center. Bone Marrow Transplant 2012; 47: 1312-1317.
5. Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant 2009; 15: 1628-1633.
6. Weisdorf D, Spellman S, Haagenson M, Horowitz M, Lee S, Anasetti C et al. Classification of HLA-matching for retrospective analysis of unrelated donor transplantation: revised definitions to predict survival. Biol Blood Marrow Transplant 2008; 14: 748-758.
7. Klein J, Moeschberger M. Survival Analysis: Techniques of Censored and Truncated Data. 2nd edn. (Springer-Verlag: New York, NY, USA, 2003).
8. Kaplan E. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
9. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995; 15: 825-828.
10. Cox DR. Regression models and life tables. J R Stat Soc 1972; 34: 187-220.
11. Burzynski JA, Toro JJ, Patel RC, Lee S, Greene RE, Ochoa-Bayona JL et al. Toxicity of a second autologous peripheral blood transplant in patients with relapsed or recurrent multiple myeloma. Leuk Lymphoma 2009; 50: 1442-1447.
12. Olin RL, Vogl DT, Porter DL, Luger SM, Schuster SJ, Tsai DE et al. Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma. Bone Marrow Transplant 2009; 43: 417-422.
13. Fenk R, Liese V, Neubauer F, Bruns I, Kondakci M, Balleisen S et al. Predictive factors for successful salvage high-dose therapy in patients with multiple myeloma relapsing after autologous blood stem cell transplantation. Leuk Lymphoma 2011; 52: 1455-1462.
14. Jimenez-Zepeda VH, Mikhael J, Winter A, Franke N, Masih-Khan E, Trudel S et al. Second autologous stem cell transplantation as salvage therapy for multiple myeloma: impact on progression-free and overall survival. Biol Blood Marrow Transplant 2012; 18: 773-779.
15. Shah N, Ahmed F, Bashir Q, Qureshi S, Dinh Y, Rondon G et al. Durable remissions with salvage second autotransplants in patients with multiple myeloma. Cancer 2012; 118: 3549-3555.
16. Chow AW, Lee CH, Hiwase DK, To LB, Horvath N. Relapsed multiple myeloma: who benefits from salvage autografts? Intern Med J 2013; 43: 156-161.
17. Michaelis LC, Saad A, Zhong X, Le-Rademacher J, Freytes CO, Marks DI et al. Salvage second hematopoietic cell transplantation in myeloma. Biol Blood Marrow Transplant. 2013; 19: 760-766.
18. Badros A, Barlogie B, Morris C, Desikan R, Martin SR, Munshi N et al. High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions. Blood 2001; 97: 2574-2579.
19. Kroger N, Sayer HG, Schwerdtfeger R, Kiehl M, Nagler A, Renges H et al. Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality. Blood 2002; 100: 3919-3924.
20. Einsele H, Schafer HJ, Hebart H, Bader P, Meisner C, Plasswilm L et al. Follow-up of patients with progressive multiple myeloma undergoing allografts after reduced-intensity conditioning. Br J Haematol 2003; 121: 411-418.
21. Gerull S, Goerner M, Benner A, Hegenbart U, Klein U, Schaefer H et al. Long-term outcome of nonmyeloablative allogeneic transplantation in patients with high-risk multiple myeloma. Bone Marrow Transplant 2005; 36: 963-969.
22. Pérez-Simón JA, Sureda A, Fernández-Aviles F, Sampol A, Cabrera JR, Caballero D et al. Reduced-intensity conditioning allogeneic transplantation is associated with a high incidence of extramedullary relapses in multiple myeloma patients. Leukemia 2006; 20: 542-545.
23. Qazilbach MH, Saliba R, De Lima M, Hosing C, Couriel D, Aleman A et al. Second autologous or allogeneic transplantation after the failure of first autograft in patients with multiple myeloma. Cancer 2006; 106: 1084-1089.
24. Georges GE, Maris MB, Maloney DG, Sandmaier BM, Sorror ML, Shizuru JA et al. Nonmyeloablative unrelated donor hematopoietic cell transplantation to treat patients with poor-risk, relapsed, or refractory multiple myeloma. Biol Blood Marrow Transplant 2007; 13: 423-432.
25. Majolino I, Davoli M, Carnevalli E, Locasciulli A, Di Bartolomeo P, Scime R et al. Reduced intensity conditioning with thiotepa, fludarabine, and melphalan is effective in advanced multiple myeloma. Leuk Lymphoma 2007; 48: 759-766.
26. De Lavallade H, El-Cheikh J, Faucher C, Furst S, Stoppa AM, Coso D et al. Reduced-intensity conditioning allogeneic SCT as salvage treatment for relapsed multiple myeloma. Bone Marrow Transplant 2008; 41: 953-960.
27. Osman K, Elliot B, Mandeli J, Scigliano E, Malone A, Isola L et al. Non-myeloablative conditioning and allogeneic transplantation for multiple myeloma. Am J Hematol 2010; 85: 249-254.
28. Shimoni A, Hardan I, Ayuk F, Schilling G, Atanackovic D, Zeller W et al. Allogenic hematopoietic stem cell transplantation with reduced-intensity conditioning in patients with refractory and recurrent multiple myeloma. Cancer 2010; 116: 3621-3630.
29. Crawley C, Lallancete M, Szydlo R, Gilleece M, Peggs K, Mackinnon S et al. Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors of the Leukemia Working Party of the EBMT. Blood 2005; 105: 4532-4539.
30. Krishnan A, Pasquini MC, Logan B, Stadtmauer EA, Vesole DH, Alyea III E et al. Tandem autologous versus single autologous transplantation followed by allo-geneic hematopoietic cell transplantation for patients with multiple myeloma: results from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0102 trial. Lancet Oncol 2011; 12: 1195-1203.